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On September 14–15, 2015, a meeting of clinicians and investigators in the fields of veterinary and human neuro-oncology, clin-
ical trials, neuropathology, and drug development was convened at the National Institutes of Health campus in Bethesda, Mary-
land. This meeting served as the inaugural event launching a new consortium focused on improving the knowledge, development
of, and access to naturally occurring canine brain cancer, specifically glioma, as amodel for human disease. Within the meeting, a
SWOT (strengths, weaknesses, opportunities, and threats) assessment was undertaken to critically evaluate the role that naturally
occurring canine brain tumors could have in advancing this aspect of comparative oncology aimed at improving outcomes for
dogs and human beings. A summary of this meeting and subsequent discussion are provided to inform the scientific and clinical
community of the potential for this initiative. Canine and human comparisons represent an unprecedented opportunity to com-
plement conventional brain tumor research paradigms, addressing a devastating disease for which innovative diagnostic and
treatment strategies are clearly needed.
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The past several decades have witnessed remarkable advances
in our understanding of human cancers on a genomic level, and
hence have provided new opportunities to implement the
practice of personalized medicine. The pharmaceutical industry
has invested substantial resources, in both capital and research
effort, to identify new cancer drugs that might provide a major
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positive impact on cancer patient survival. Disappointingly,
identification of new agents to improve cancer treatment
remains elusive for many lethal cancers, with approximately
1 in 4 deaths in the United States being attributed to cancer
annually (Cancer Facts & Figures 2015; www.cancer.org). This
has been particularly true for malignant primary brain tumors,
for which there have been only 2 new therapeutic agents ap-
proved over the last 2 decades.1 The pathway to successful
cancer drug discovery remains difficult and expensive despite
significant economic investment, and the development of
breakthrough novel therapeutics to match the impact of com-
pounds such as imatinib remains extremely infrequent. Given
these challenges, there is potential for the pharmaceutical in-
dustry to become too risk averse and for the advancement of
effective novel therapeutic discovery to ultimately slow. An
improved drug development paradigm facilitated by the utiliza-
tion of more predictive and accurate preclinical models would
offer opportunities to mitigate some of the risk associated with
drug development. Such an alternative strategy could be sub-
stantively enabled by comparative tumor oncology, pathology,
and genomics through the inclusion of companion animals
with naturally occurring cancer.2,3
Comparative oncology is a growing field of study centered
around investigation of naturally occurring cancers in nonhu-
man species, such as pet dogs, as a parallel and complemen-
tary model for human cancer research efforts.4–6 Like humans,
pet dogs naturally develop primary central nervous system
neoplasms that encompass a wide variety of tumor histologies,
including, but not limited to, glial tumors (astrocytomas, oligo-
dendrogliomas), meningiomas, and pituitary gland tumors.7 At
this time the pet dog is the most widely studied companion an-
imal species, due primarily to the degree of genome similarity,
shared environment, and the incidence of diagnosed spontane-
ous canine cancers reported each year in the US. The promise of
comparative oncology and the specific role of the domestic dog
formed the basis of a recent review in a special issue of the
Royal Society’s journal, and highlights the global opportunities
for advancing medicine through the inclusion of naturally oc-
curring canine disease models.8
The incidence of brain tumors in dogs is approximately 2%–
4.5% based upon necropsy-dependent surveys and is likely an
underestimation given the practical limitations of veterinary
medical care.9,10 Most descriptive studies agree that approxi-
mately 50% of primary brain tumors are meningioma, with gli-
omas representing 30%–40% and the remaining comprising
choroid plexus tumors, ependymoma, and primitive neuroecto-
dermal tumors. Specific breeds are known to have significantly
increased risk of primary intracranial tumor development,
namely the Boxer, Boston Terrier, Golden Retriever, French Bull-
dog, Miniature Schnauzer, and Rat Terrier.10
Recent improvements in the diagnosis and management of
canine brain tumors are largely due to the broad adoption of
cross-sectional imaging techniques (CTand MRI) within the vet-
erinary medical community, coupled with growing expertise
and collective clinical experience among veterinary specialists
in neurosurgical techniques, radiation therapy protocols, and
use of chemotherapy. However, most therapeutic studies in
dogs with brain tumors are descriptive in nature, and the con-
clusions are limited by retrospective study design and small pa-
tient numbers, along with a lack of standardization in tumor
biopsy and/or imaging endpoints across studies. In the absence
of prospective and rational clinical trial design, fundamental
gaps in knowledge regarding canine brain tumor biology and
therapeutic response persist within the veterinary scientific
community, and advancement has been hindered by the chal-
lenges posed by limitations of the late-stage diagnosis of intra-
cranial disease, the morbidity associated with intracranial
procedures such as biopsy/surgical resection and external
beam irradiation, and, not inconsequentially, pet owners’ dis-
posable income.9,11 Despite these limitations, available prelim-
inary data suggest that core oncogenic pathways defined in
human brain tumors may be implicated in dog tumors, sup-
porting a more detailed and thorough evaluation of the
model.12–18
Although much is known about the clinical outcomes, imag-
ing characteristics, and breed predilection for certain intracrani-
al malignancies, there is a paucity of data to enable accurate
statistics to catalog true incidence and natural disease history
or to establish histologic and molecular relevance to human
brain tumors. Despite the expertise and training afforded by
American College of Veterinary Internal Medicine specialists in
oncology and neurology, as well as critically aligned fields and
specialty colleges such as pathology, imaging, neurology, and
surgery since the mid-1980s, much remains unknown regard-
ing themolecular underpinnings of canine cancers to better op-
timize prevention and patient care. Therefore, there are
recognized, but not insurmountable, limitations in being able
to assess the true potential of including pet dogs with brain
cancers as predictive models to advance therapies for human
use. By organizing a focused initiative aimed at overcoming a
number of these challenges, the potential inclusion of dogs
with brain cancer as a sophisticated preclinical model of
human patients offers several advantages for expediting drug
discovery and development efforts.19
Comparative oncology is now being advanced as a research
discipline by many diverse research institutions. The National
Cancer Institute’s (NCI) Comparative Oncology Program (COP)
is a collaborative group, utilizing an extramural clinical trial con-
sortium (Comparative Oncology Trials Consortium [COTC]) (Fig. 1)
with a demonstrable track record in conducting high-quality sci-
entifically robust clinical trials with a variety of sponsors to ad-
dress drug development questions that would be difficult to
study in the context of conventional animal models of cancer
and/or to overcome developmental barrier issues not feasible
within the human clinical trial setting.20,21 The COTC mechanism
provides a facile method for recruiting dogs frommultiple partic-
ipating veterinary academic institutions. Funding for these trials
comes from a variety of sources, including but not limited to the
pharmaceutical industry, philanthropic organizations, and NCI.
Study support provided to veterinarians caring for dogs enrolled
in COTC trials includes clinical veterinary care, conduct of correl-
ative assays on biologic samples, and in some cases financial
support to owners for future veterinary care for their pet after
the study concludes. This group has historically relied on veteri-
nary medical oncologists as the institutional COTC investigators.
The comparative aspects of canine brain tumors have not been
previously studied within the context of a COTC clinical trial.
Inconsistent availability of expertise in the field of veterinary
neuro-oncology may be a reason that canine brain tumors
have not been sufficiently explored as a model for human
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brain cancer. To address this challenge, we seek directed im-
provements in cooperation of veterinary neurologists, surgeons,
and radiation oncologists who manage dogs with intracranial
malignancies with other neuro-oncology investigators. Indeed,
the somewhat “siloed” nature of research environments and re-
liance on single-institution efforts result in potentially biased in-
cidence rates and sample populations and small numbers of
samples and/or patients being reported in any given aspect of
such research.
Human brain tumor research would benefit from a similar
need to improve our understanding of the molecular drivers
of the disease. However, many novel strategies could potential-
ly be borne out of a deeper understanding of tumor biology via
The Cancer Genome Atlas and other efforts in molecular char-
acterization which are supporting drug discovery.22,23 The lim-
itations of current conventional animal models still impede
forward progress. Murine models of brain cancer can be in-
duced via cell line or patient-derived xenograft techniques or
be the result of molecular manipulation, but do not recapitu-
late all facets of naturally occurring disease.24–27 One of the
main obstacles for leveraging the comparative approach for
brain tumor research is insufficient evidence that these
mouse and rat models translate to human disease; this in-
cludes the lack of consensus among histopathology, molecular
markers, genomics, and clinical outcome data.
Organized research groups such as the Collaborative Epen-
dymoma Research Network (CERN) provide a roadmap to
guide the organization and forward progress of the COP/COTC
and other comparative initiatives.28 –30 This initiative uses a
working-group format that unifies multidisciplinary teams
around central themes (pathology/molecular markers, tumor
biology/immunology, drug discovery, clinical trials, and patient
outcomes) to facilitate discussions and exchange of knowl-
edge. CERN’s mission and infrastructure were utilized as guiding
principles for the discussions during this meeting.
The meeting convened at the National Institutes of Health
had 3 main goals:
(1) Establish a collaborative research network with an immediate
goal of sharing cross-discipline experiences and knowledge.
(2) Define a working group structure (Fig. 2) that could be pop-
ulated with cross-discipline experts from the allied fields of
veterinary medicine, human medicine, and basic research.
Fig. 1. A map of the Comparative Oncology Trials Consortium (COTC).
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(3) Define the goals of the consortium efforts in a project-
based format for each working group.
Herein we present a consensus of the opportunities and chal-
lenges identified within the summary of each working group
discussion and provide an agenda that can be used to advance
this field for the bidirectional benefit of both humans and dogs
with this challenging disease.
Strengths
The wide variety of brain tumor histologies that dogs spontane-
ously develop, including but not limited to glial tumors (astrocy-
tomas, oligodendrogliomas), meningiomas, and pituitary gland
tumors, are an obvious strength of the comparative approach.
A focus on the dog as a model for human gliomas specifically
(Fig. 3), as a first priority for tissue-based projects, was consis-
tently identified among all 5 working groups as most immedi-
ately impactful for improving both human and dog outcomes.
A noteworthy advantage of the companion dog model is that
spontaneous disease in an immune-competent host is critical
for developing immunomodulatory therapies.31,32 Similar physi-
cal size and vascular biology should facilitate investigation of the
role of the blood–brain barrier and how it limits drug therapies,
along with comparable pharmacokinetics (PK) (and potentially
pharmacodynamics [PD]) to facilitate dose finding in early clini-
cal studies. Realistic assessments of novel physical delivery/ther-
apeutic strategies have already been demonstrated across
several different approaches using dog tumors as a model plat-
form.33–36 Finally and most importantly, disease heterogeneity,
particularly genomic and epigenomic heterogeneity, is a critical
attribute of canine and human brain cancers that cannot be
accurately modeled in conventional animal model approaches
to date.
From a clinical trial perspective, one particular strength/op-
portunity of the canine brain tumormodel in drug development
is the initiation of phase 0 studies—small-cohort studies in
which the primary endpoints of investigation are (i) target mod-
ulation: confirmed and serially evaluated (diagnosis, surgery,
necropsy), (ii) outcome assessment: radiological or clinical met-
rics of drug effect, and (iii) biodistribution, PK, and PD endpoints
to enable identification of “effective exposure” correlated to
target modulation while also supporting discovery and valida-
tion of biomarkers representative of outcome effect. Several ex-
amples of such studies in other canine cancers exist in the
scientific literature and form a basis for such endeavors in
brain tumor drug development.37–40
Clinical trials in pet dogs with cancer and a variety of other
diseases are routinely carried out at veterinary academic cen-
ters that evaluate investigational therapies under the care and
direction of veterinary specialists in a wide range of disciplines.
Clinical care is provided within the veterinary teaching hospital
by highly trained teams of veterinary clinicians and technicians
according to a standardized protocol. There are specific oppor-
tunities for dogs with brain tumors to participate in a clinical
trial offered alongside standard treatments, such as surgical re-
section and external beam radiotherapy. In this situation, own-
ers have the ability to choose the best option for their pet based
upon their financial resources and goals and expectations for
their pet’s outcome. Funding for such clinical trials is obtained
through grants and/or research contracts via philanthropic
Fig. 2. A schematic representation of the participating groups within the Comparative Brain Tumor Consortium.
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agencies or pharmaceutical companies. Dogs are recruited
from the community by participating sites using a variety of
social networking, mail, and web-based advertising techniques.
The conduct of COTC trials is centrally managed by the NCI-
COP, with input from a Data Safety Monitoring Board convened
for each trial. Data from these trials are presented and
published in the proceedings of national and international
meetings as well as in the biomedical research literature.
The cost/benefit rationale for performing comparative stud-
ies in tumor-bearing pet dogs prior to or in parallel with human
clinical trials was recently discussed at a National Academies
workshop entitled “The Role of Clinical Studies for Pets with
Fig. 3. Representative photomicrographs of high-grade (WHO grade III) cerebral oligodendrogliomas in humans, dogs, and mice. (A) Human
high-grade oligodendroglioma contains a delicate “chicken wire” vasculature and mucin-rich microcystic spaces and is composed of neoplastic
cells with oval, hyperchromatic nuclei, and clear cytoplasm. (B) Higher magnification of a human high-grade oligodendroglioma shows tumor
nuclei with crisp nuclear borders and abundant mitoses. (C) A surgical biopsy of a high-grade (grade III) cerebral oligodendroglioma in a
Boston Terrier, demonstrating clear cytoplasm and distinct cell membranes, with ovoid hyperchromatic nuclei. (D) Higher magnification
highlights endothelial hyperplasia of this lesion. (E) A high-grade oligodendroglioma allograft from a mouse stereotactically injected with
oligodendrocyte progenitor cells harboring deletion mutations in transformation related protein 53 and neurofibromatosis type 1 (Ref PMID
25246577) shows similar features, including (F) the delicate vasculature and microcystic spaces and nuclei with crisp nuclear membranes and
abundant mitoses. All sections were stained with hematoxylin and eosin. Original magnifications: 200× (A), 600× (B), 200× (C), 400× (D), 400×
(E), 600× (F). Scale bars¼ 50 mm. Human and murine images courtesy of Dr C. Ryan Miller, University of North Carolina School of Medicine. Canine
images courtesy of Dr R. Timothy Bentley, Purdue University College of Veterinary Medicine.
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Naturally Occurring Tumors in Translational Cancer Research”
(http://iom.nationalacademies.org/Activities/Disease/NCPF/
2015-JUN-08.aspx).41 Of the many advantages to studying
cancer in dogs for the purposes of human cancer drug devel-
opment, one significant benefit is the ability to evaluate novel
therapies in treatment-naı¨ve disease, particularly when dogs’
owners are not able or interested in pursuing conventional
treatments for their pet. This allows interrogation of relation-
ships between drug target and drug exposure within a natural-
ly occurring tumor that has not been extensively pretreated
with other therapies and thus may provide a more accurate
assessment of that drug’s potential for human use. The
value of the comparative approach is highlighted by the
unique opportunities to explore PK/PD relationships over a
range of doses, including serial tissue and biologic sample col-
lections, and the ability to make changes to the study protocol
in response to data in real time.42
Imaging agent and device development can also uniquely
benefit from the physical size of dogs’ brains, and several exam-
ples demonstrate the opportunities to evaluate prototype devices
(eg, convection-enhanced delivery catheters, stereotactic radio-
surgery) utilizing the same or similar clinical technologies that
are routinely used in human cancer treatment. To facilitate
such efforts, most veterinary medical centers that routinely diag-
nose and treat dogs with brain tumors maintain state-of-the-art
imaging and therapeutic technologies, such as CT and/or high-
strength MRI for brain imaging and stereotactic brain biopsy,
interventional radiology suites, and linear accelerators for radio-
therapy (Fig. 4).43–50
Weaknesses: Where Are the Critical Gaps in This Field?
Limitations include a paucity of knowledge about the natural
history of disease progression and its impact on clinical diagno-
sis, which can be addressed by a robust survey of veterinarians
involved in the diagnosis, management, and treatment of such
pets. Most diagnoses of brain cancer in dogs come when signif-
icant neurologic deficits and/or seizures are noted, thus tumors
are often large and responses even to aggressive therapy are
poor.9,51,52 The advanced stage of these tumors may actually
lend itself to a new era of collaboration between veterinary
and physician neurologists and neurosurgeons, particularly in
the area of complex neurosurgical approaches wherein achiev-
ing a gross total resection may be of high prognostic value for
the canine patient based upon the human literature.53–55
The lack of standardized methods to evaluate response to
therapy limits investigation of patterns of recurrence. This too
can be addressed via consensus documents generated within
the veterinary community. The lack of robust incidence and
prevalence estimates, which may be intensely biased by pat-
terns of care, can be addressed in a similar fashion. Some
unique features of veterinary medicine are that many patients
remain untreated, as dog owners have an option for early
election of humane euthanasia, and the overriding impact of
finance-driven decisions influences selection biases in treat-
ment. These issues can skew estimates of the true incidence
of disease among pet dogs, as well as effectiveness of
therapies and outcomes data.
The current lack of understanding of molecular underpin-
nings that may drive genetics of tumorigenesis and progression
in both dogs and humans leaves open the possibility that these
may differ between dogs and humans in substantial ways. This
area, including an improved understanding of the molecular
basis for brain cancer development in dogs, should receive
major emphasis in future research. Successful inclusion of pet
dogs with brain cancer into the drug discovery and develop-
ment pathway will require additional resources and research
to confirm the suitability of the pet dog as a reliable preclinical
model of human cancer patients. This also would require the
thorough characterization and annotation of the canine im-
mune system and its response to neoplasia, as well as confir-
mation that brain cancers that arise naturally in dogs possess
similar or overlapping histopathological, molecular, and genetic
signatures as those in human cancer patients. Some data have
been generated in the field to address these critical gaps, but
larger studies are clearly needed.12,15,24,56–59
Opportunities: How to Address the Weaknesses and
Advocate for the Strengths of the Canine Cancer Model
Each working group generated a robust list of concepts and
specific projects in direct response to the acknowledged
Fig. 4. High-grade (grade III) cerebral oligodendroglioma in a Boxer dog. (A) T1-weighted post-contrast transverse MRI. An intra-axial mass lesion
displays mixed contrast enhancement and partial ring enhancement. (B) Intraoperative image. A gray lesion has indistinct margins with the
surrounding cerebrum. (C) Photomicrograph, surgical biopsy, hematoxylin and eosin. Neoplastic cells have ovoid, hyperchromatic nuclei and
clear cytoplasm. Nuclei are ovoid and hyperchromatic. (D) Postoperative T1-weighted post-contrast MRI. There is no evidence of the previous
mass. The adjacent lateral ventricle is displaced toward the resection cavity. Note the bone defect associated with previous craniectomy.
Images courtesy of Dr R. Timothy Bentley, Purdue University College of Veterinary Medicine.
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strengths and weaknesses of studying and utilizing the canine
brain cancer model. Creation of a central tissue registry, a cen-
tral catalog of veterinary institutions highlighting their individu-
al fixed technology/infrastructure, expertise, resources in
support of clinical trials, and development of consensus proto-
cols were all considered key to rapid advancement of the field
with a critical mass of investigators, knowledge, and materials.
The largest opportunity facing this initiative is to substantiate
valid translation to human disease, and then to leverage this
unique model for funding activities to support large-scale
investigations.
Opportunities to expand upon the existing, albeit limited,
knowledge of canine brain tumors begin with the fact that
many veterinary institutions have existing tumor banks in var-
ious forms (formalin-fixed paraffin-embedded/frozen) which
could support a multiplatform integrative molecular analysis
analogous to that performed by The Cancer Genome Atlas on
retrospective cohorts, thus helping to establish canine tumor
molecular genetic landscapes for comparison with hu-
mans.60,61 This could include single nucleotide variant and
copy number alterations, expression and methylation profiles,
comprehensive histopathological characterization to establish
diagnostic criteria with comparisons with analogous human tu-
mors, and characterization of tumor immunology via immuno-
histochemistry and related expression profiles.
Such an effort would begin with the development of an up-
dated classification and grading scheme for canine gliomas.
The pathology and molecular markers working group felt that
developing such a scheme would promote uniformity in diag-
nosis across institutions and improve understanding in making
comparisons with human adult and pediatric glial tumors. This
initiative was envisioned to take place in 2 distinct phases: first,
a retrospective pathologic assessment of approximately 200
hematoxylin and eosin stained glass slides of treatment-naı¨ve
canine gliomas of all subtypes and grades by both veterinary
and physician neuropathologists from multiple participating in-
stitutions. High-resolution images will be centrally scanned and
hosted digitally, and a consensus panel of a minimum of 6 of
each physician and veterinary pathologists would develop a
consensus on clear, concise criteria for classification and grad-
ing; these should be based whenever possible on the current
humanWorld Health Organization system to allow for compar-
ison but should incorporate species-specific features as identi-
fied and agreed upon. A subgroup of tumors (formalin-fixed
paraffin-embedded tissue) that were optimally stored and
characterized for this review would then be selected for expres-
sion of pertinent molecular markers (such as glial fibrillary acidic
protein, vimentin, Olig2, CNPase, synaptophysin, neurofilament
M, neuronal nuclei/beta-III tubulin/neurofilament, and Ki67).62
This will be performed using immunohistochemistry to allow fur-
ther uniformity in diagnosis and comparisons between human
adult and pediatric glial tumors. Development and optimization
of the appropriate species-specific reagents to interrogate addi-
tional markers of molecular pathogenesis, such as protein 53,
alpha thalassemia/mental retardation syndrome X-linked, beta-
catenin, and integrase interactor 1, would be valuable in this
context and could also be assessed in the setting of RNA
sequencing or other techniques.
Second, this group proposed genomic analyses and expres-
sion profiling of 50 canine high-grade gliomas meeting these
newly revised classification criteria to allow for comparison
with human adult and pediatric glial tumors, and to generate
potential pharmacologic targets for canine patients. This aspect
of the project will be both retrospective and prospective in na-
ture. For the retrospective portion, snap-frozen tissue from insti-
tutions with paired banked formalin-fixed paraffin-embedded
tissue from glial tumors which have been histopathology-
confirmed within the newly proposed grading and classification
scheme will be subjected to whole-exome and RNA sequencing.
For the prospective portion, kits and detailed standard operating
procedures (SOPs) will be distributed to selected sites, both aca-
demic institutions and private practices, for the collection of
tumor specimens. Samples will be snap-frozen tissue or tissue
in RNAlater and formalin-fixed tissue. Samples will be stored at
a central biobank location and subjected to histopathological
confirmation, whole-exome sequencing, and RNA sequencing,
as funding is available. Sequence information will be subjected
to informatics, processed, and shared publicly as soon as publi-
cation ready. Collection of tissues and sharing of data for public
dissemination to advance these goals was felt to be optimally
facilitated by the NCI-COP. The NCI is ideally positioned to take
a leadership role in this effort, as demonstrated within other
comparative oncology initiatives.63
If successful, the above effort could be used to create infra-
structure that would facilitate establishing a multi-institutional
collaboration for prospective tissue banking in order to estab-
lish best practices for tissue collection and establish SOPs for
analysis and public dissemination of data. This could be fol-
lowed by formation of a multi-institutional cooperative group
for generating patient-derived xenografts and cell lines to facil-
itate in vitro and in vivo studies alongside a multi-institutional
cooperative clinical trials group to establish standards of diag-
nosis (pathology and imaging), treatment (surgery, radiation
and chemotherapy), and definition of outcomes (pathology
and clinical care). Additionally, there is the opportunity to lever-
age the existing NCI-COTC infrastructure, currently comprising
22 active veterinary academic centers, many of which repre-
sent the key leaders in veterinary neurology and oncology.
The existing COTC membership and agreements for study con-
duct and data management could be expanded and/or modi-
fied to include additional collaborators.
The Patient Outcomesworking group defined a goal of the for-
mulation and validation of scales for subjective outcome data
that include quality of life measures, functional scales, pain scor-
ing, seizure frequency, mental and cognitive ability, and the influ-
ence of extent of tumor burden. Measures must be sensitive to
disease status and should be validated for interobserver varia-
tion, as well as be evaluated against natural progression of dis-
ease. Such measures can then be applied as consensus for
assessing treatment response in canine brain tumor trials. Along-
side this document, this working group suggested the ongoing
development and refinement of a consensus statement on
brain MRI protocol for veterinary facilities, following a human
consensus statement as a model to include data on instrument
brand and strength, sequences and parameters, and timing of
posttreatment and longer-term follow-up scans.64,65 This type
of consensus will directly support the comparison of dog data
with those of humans for comparative studies within multi-
institutional clinical research and identify those scan protocols
and MRI sequences that aremost useful in patient management.
Review
Neuro-Oncology 7 of 10
Review
Neuro-Oncology 1215
Naturally Occurring Tumors in Translational Cancer Research”
(http://iom.nationalacademies.org/Activities/Disease/NCPF/
2015-JUN-08.aspx).41 Of the many advantages to studying
cancer in dogs for the purposes of human cancer drug devel-
opment, one significant benefit is the ability to evaluate novel
therapies in treatment-naı¨ve disease, particularly when dogs’
owners are not able or interested in pursuing conventional
treatments for their pet. This allows interrogation of relation-
ships between drug target and drug exposure within a natural-
ly occurring tumor that has not been extensively pretreated
with other therapies and thus may provide a more accurate
assessment of that drug’s potential for human use. The
value of the comparative approach is highlighted by the
unique opportunities to explore PK/PD relationships over a
range of doses, including serial tissue and biologic sample col-
lections, and the ability to make changes to the study protocol
in response to data in real time.42
Imaging agent and device development can also uniquely
benefit from the physical size of dogs’ brains, and several exam-
ples demonstrate the opportunities to evaluate prototype devices
(eg, convection-enhanced delivery catheters, stereotactic radio-
surgery) utilizing the same or similar clinical technologies that
are routinely used in human cancer treatment. To facilitate
such efforts, most veterinary medical centers that routinely diag-
nose and treat dogs with brain tumors maintain state-of-the-art
imaging and therapeutic technologies, such as CT and/or high-
strength MRI for brain imaging and stereotactic brain biopsy,
interventional radiology suites, and linear accelerators for radio-
therapy (Fig. 4).43–50
Weaknesses: Where Are the Critical Gaps in This Field?
Limitations include a paucity of knowledge about the natural
history of disease progression and its impact on clinical diagno-
sis, which can be addressed by a robust survey of veterinarians
involved in the diagnosis, management, and treatment of such
pets. Most diagnoses of brain cancer in dogs come when signif-
icant neurologic deficits and/or seizures are noted, thus tumors
are often large and responses even to aggressive therapy are
poor.9,51,52 The advanced stage of these tumors may actually
lend itself to a new era of collaboration between veterinary
and physician neurologists and neurosurgeons, particularly in
the area of complex neurosurgical approaches wherein achiev-
ing a gross total resection may be of high prognostic value for
the canine patient based upon the human literature.53–55
The lack of standardized methods to evaluate response to
therapy limits investigation of patterns of recurrence. This too
can be addressed via consensus documents generated within
the veterinary community. The lack of robust incidence and
prevalence estimates, which may be intensely biased by pat-
terns of care, can be addressed in a similar fashion. Some
unique features of veterinary medicine are that many patients
remain untreated, as dog owners have an option for early
election of humane euthanasia, and the overriding impact of
finance-driven decisions influences selection biases in treat-
ment. These issues can skew estimates of the true incidence
of disease among pet dogs, as well as effectiveness of
therapies and outcomes data.
The current lack of understanding of molecular underpin-
nings that may drive genetics of tumorigenesis and progression
in both dogs and humans leaves open the possibility that these
may differ between dogs and humans in substantial ways. This
area, including an improved understanding of the molecular
basis for brain cancer development in dogs, should receive
major emphasis in future research. Successful inclusion of pet
dogs with brain cancer into the drug discovery and develop-
ment pathway will require additional resources and research
to confirm the suitability of the pet dog as a reliable preclinical
model of human cancer patients. This also would require the
thorough characterization and annotation of the canine im-
mune system and its response to neoplasia, as well as confir-
mation that brain cancers that arise naturally in dogs possess
similar or overlapping histopathological, molecular, and genetic
signatures as those in human cancer patients. Some data have
been generated in the field to address these critical gaps, but
larger studies are clearly needed.12,15,24,56–59
Opportunities: How to Address the Weaknesses and
Advocate for the Strengths of the Canine Cancer Model
Each working group generated a robust list of concepts and
specific projects in direct response to the acknowledged
Fig. 4. High-grade (grade III) cerebral oligodendroglioma in a Boxer dog. (A) T1-weighted post-contrast transverse MRI. An intra-axial mass lesion
displays mixed contrast enhancement and partial ring enhancement. (B) Intraoperative image. A gray lesion has indistinct margins with the
surrounding cerebrum. (C) Photomicrograph, surgical biopsy, hematoxylin and eosin. Neoplastic cells have ovoid, hyperchromatic nuclei and
clear cytoplasm. Nuclei are ovoid and hyperchromatic. (D) Postoperative T1-weighted post-contrast MRI. There is no evidence of the previous
mass. The adjacent lateral ventricle is displaced toward the resection cavity. Note the bone defect associated with previous craniectomy.
Images courtesy of Dr R. Timothy Bentley, Purdue University College of Veterinary Medicine.
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strengths and weaknesses of studying and utilizing the canine
brain cancer model. Creation of a central tissue registry, a cen-
tral catalog of veterinary institutions highlighting their individu-
al fixed technology/infrastructure, expertise, resources in
support of clinical trials, and development of consensus proto-
cols were all considered key to rapid advancement of the field
with a critical mass of investigators, knowledge, and materials.
The largest opportunity facing this initiative is to substantiate
valid translation to human disease, and then to leverage this
unique model for funding activities to support large-scale
investigations.
Opportunities to expand upon the existing, albeit limited,
knowledge of canine brain tumors begin with the fact that
many veterinary institutions have existing tumor banks in var-
ious forms (formalin-fixed paraffin-embedded/frozen) which
could support a multiplatform integrative molecular analysis
analogous to that performed by The Cancer Genome Atlas on
retrospective cohorts, thus helping to establish canine tumor
molecular genetic landscapes for comparison with hu-
mans.60,61 This could include single nucleotide variant and
copy number alterations, expression and methylation profiles,
comprehensive histopathological characterization to establish
diagnostic criteria with comparisons with analogous human tu-
mors, and characterization of tumor immunology via immuno-
histochemistry and related expression profiles.
Such an effort would begin with the development of an up-
dated classification and grading scheme for canine gliomas.
The pathology and molecular markers working group felt that
developing such a scheme would promote uniformity in diag-
nosis across institutions and improve understanding in making
comparisons with human adult and pediatric glial tumors. This
initiative was envisioned to take place in 2 distinct phases: first,
a retrospective pathologic assessment of approximately 200
hematoxylin and eosin stained glass slides of treatment-naı¨ve
canine gliomas of all subtypes and grades by both veterinary
and physician neuropathologists from multiple participating in-
stitutions. High-resolution images will be centrally scanned and
hosted digitally, and a consensus panel of a minimum of 6 of
each physician and veterinary pathologists would develop a
consensus on clear, concise criteria for classification and grad-
ing; these should be based whenever possible on the current
humanWorld Health Organization system to allow for compar-
ison but should incorporate species-specific features as identi-
fied and agreed upon. A subgroup of tumors (formalin-fixed
paraffin-embedded tissue) that were optimally stored and
characterized for this review would then be selected for expres-
sion of pertinent molecular markers (such as glial fibrillary acidic
protein, vimentin, Olig2, CNPase, synaptophysin, neurofilament
M, neuronal nuclei/beta-III tubulin/neurofilament, and Ki67).62
This will be performed using immunohistochemistry to allow fur-
ther uniformity in diagnosis and comparisons between human
adult and pediatric glial tumors. Development and optimization
of the appropriate species-specific reagents to interrogate addi-
tional markers of molecular pathogenesis, such as protein 53,
alpha thalassemia/mental retardation syndrome X-linked, beta-
catenin, and integrase interactor 1, would be valuable in this
context and could also be assessed in the setting of RNA
sequencing or other techniques.
Second, this group proposed genomic analyses and expres-
sion profiling of 50 canine high-grade gliomas meeting these
newly revised classification criteria to allow for comparison
with human adult and pediatric glial tumors, and to generate
potential pharmacologic targets for canine patients. This aspect
of the project will be both retrospective and prospective in na-
ture. For the retrospective portion, snap-frozen tissue from insti-
tutions with paired banked formalin-fixed paraffin-embedded
tissue from glial tumors which have been histopathology-
confirmed within the newly proposed grading and classification
scheme will be subjected to whole-exome and RNA sequencing.
For the prospective portion, kits and detailed standard operating
procedures (SOPs) will be distributed to selected sites, both aca-
demic institutions and private practices, for the collection of
tumor specimens. Samples will be snap-frozen tissue or tissue
in RNAlater and formalin-fixed tissue. Samples will be stored at
a central biobank location and subjected to histopathological
confirmation, whole-exome sequencing, and RNA sequencing,
as funding is available. Sequence information will be subjected
to informatics, processed, and shared publicly as soon as publi-
cation ready. Collection of tissues and sharing of data for public
dissemination to advance these goals was felt to be optimally
facilitated by the NCI-COP. The NCI is ideally positioned to take
a leadership role in this effort, as demonstrated within other
comparative oncology initiatives.63
If successful, the above effort could be used to create infra-
structure that would facilitate establishing a multi-institutional
collaboration for prospective tissue banking in order to estab-
lish best practices for tissue collection and establish SOPs for
analysis and public dissemination of data. This could be fol-
lowed by formation of a multi-institutional cooperative group
for generating patient-derived xenografts and cell lines to facil-
itate in vitro and in vivo studies alongside a multi-institutional
cooperative clinical trials group to establish standards of diag-
nosis (pathology and imaging), treatment (surgery, radiation
and chemotherapy), and definition of outcomes (pathology
and clinical care). Additionally, there is the opportunity to lever-
age the existing NCI-COTC infrastructure, currently comprising
22 active veterinary academic centers, many of which repre-
sent the key leaders in veterinary neurology and oncology.
The existing COTC membership and agreements for study con-
duct and data management could be expanded and/or modi-
fied to include additional collaborators.
The Patient Outcomesworking group defined a goal of the for-
mulation and validation of scales for subjective outcome data
that include quality of life measures, functional scales, pain scor-
ing, seizure frequency, mental and cognitive ability, and the influ-
ence of extent of tumor burden. Measures must be sensitive to
disease status and should be validated for interobserver varia-
tion, as well as be evaluated against natural progression of dis-
ease. Such measures can then be applied as consensus for
assessing treatment response in canine brain tumor trials. Along-
side this document, this working group suggested the ongoing
development and refinement of a consensus statement on
brain MRI protocol for veterinary facilities, following a human
consensus statement as a model to include data on instrument
brand and strength, sequences and parameters, and timing of
posttreatment and longer-term follow-up scans.64,65 This type
of consensus will directly support the comparison of dog data
with those of humans for comparative studies within multi-
institutional clinical research and identify those scan protocols
and MRI sequences that aremost useful in patient management.
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Threats to Advancement of the Field
In order for the scientific community to assess the potential
value of diagnoses of brain cancer in pet dogs as a valuable
and predictive preclinical model for drug discovery and develop-
ment, several key opportunities must be seized and acted upon
by leaders in the field as described above. The meeting partic-
ipants widely acknowledged that a critical first step needs to be
the establishment of a consortium of scientific and clinical in-
vestigators working toward well-defined and common goals.
These will be identified as areas of priority within the brain can-
cer community, and as such will help to galvanize these inves-
tigators to engage in continued scientific collaborations,
requiring ongoing attention and leadership within a designated
neutral third party. The NCI naturally fulfills this role with its
commitment to support of the extramural community while le-
veraging unique resources and acting as a stimulus to convene
cross-discipline audiences around topics such as comparative
oncology.
Perhaps the biggest risk facing this new consortium is the
possibility that the model of the molecular landscape of ca-
nines is not widely translatable to the human disease and/or
is limited to the study of a small subset of human tumors. If
comparative overlap is narrow, themomentum behind the con-
sortiummay be lost and a lack of buy-in from other researchers
will result in continuation of small independent projects with
lesser impact. Also acknowledged during this meeting was
the need for increased understanding by physicians of the sta-
tus of veterinary knowledge and expertise in canine brain tu-
mors, realizing that there is an ongoing need to overcome
preconceptions within the human cancer research community.
We believe that it is critical to define the comparative areas
most likely to provide informative data for cross-species thera-
peutic development, whether these are pathway targeted ther-
apies, cell targeting therapies, gross delivery/interventional
strategies, or assessment of immunomodulatory strategies.
Early goals must be attainable and informative to maintain con-
sortium momentum with a focus on defining model strengths,
which we contend are “barrier” questions that are difficult to an-
swer in rodent models or human trials but which could be an-
swered in the validated dog model with relatively small
numbers of cases. Care should be taken not to oversell the po-
tential for therapeutic outcome trials as the primary or only long-
term goal for this consortium, particularly given the logistical, fi-
nancial, and technical limitations inherent in the veterinary
neuro-oncology field. Similarly, it could be imprudent to assign
go/no-go decisions for the continuation of consortium activities
that are linked to the outcomes of experiments that have yet to
be defined. The National Academies workshop on comparative
oncology highlighted a number of critical gaps in the field,
most notably characterization of the molecular landscape of ca-
nine cancers. We agree that definition of the critical similarities
and differences that may exist in histopathological characteriza-
tion and key molecular pathways is an early and important pri-
ority. However, there are still several important facets of canine
brain cancer that make this approach a valuable complement to
traditional animal models. A significant body of published work
indicates where successes exist in the application of the compar-
ative approach to brain tumor research for the purposes of drug
development and delivery techniques.31–36 An ongoing priority
will be the advocacy and dissemination of such data to the larger
brain tumor community to maintain momentum of this
consortium.
In summary, a commitment to collaboration has been es-
tablished among veterinarians involved in canine brain tumor
patient management and physician investigators. Translational
and basic research is clearly needed for an improved under-
standing of natural disease progression and how clinical obser-
vations can be leveraged for the development of novel
treatment strategies for both dogs and humans. Further, ac-
knowledgment and appreciation of the unique strengths and
opportunities that exist between species and among veterinar-
ians and physicians are keys to establishing a consensus of
what comparative aspects are most important to the field.
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Threats to Advancement of the Field
In order for the scientific community to assess the potential
value of diagnoses of brain cancer in pet dogs as a valuable
and predictive preclinical model for drug discovery and develop-
ment, several key opportunities must be seized and acted upon
by leaders in the field as described above. The meeting partic-
ipants widely acknowledged that a critical first step needs to be
the establishment of a consortium of scientific and clinical in-
vestigators working toward well-defined and common goals.
These will be identified as areas of priority within the brain can-
cer community, and as such will help to galvanize these inves-
tigators to engage in continued scientific collaborations,
requiring ongoing attention and leadership within a designated
neutral third party. The NCI naturally fulfills this role with its
commitment to support of the extramural community while le-
veraging unique resources and acting as a stimulus to convene
cross-discipline audiences around topics such as comparative
oncology.
Perhaps the biggest risk facing this new consortium is the
possibility that the model of the molecular landscape of ca-
nines is not widely translatable to the human disease and/or
is limited to the study of a small subset of human tumors. If
comparative overlap is narrow, themomentum behind the con-
sortiummay be lost and a lack of buy-in from other researchers
will result in continuation of small independent projects with
lesser impact. Also acknowledged during this meeting was
the need for increased understanding by physicians of the sta-
tus of veterinary knowledge and expertise in canine brain tu-
mors, realizing that there is an ongoing need to overcome
preconceptions within the human cancer research community.
We believe that it is critical to define the comparative areas
most likely to provide informative data for cross-species thera-
peutic development, whether these are pathway targeted ther-
apies, cell targeting therapies, gross delivery/interventional
strategies, or assessment of immunomodulatory strategies.
Early goals must be attainable and informative to maintain con-
sortium momentum with a focus on defining model strengths,
which we contend are “barrier” questions that are difficult to an-
swer in rodent models or human trials but which could be an-
swered in the validated dog model with relatively small
numbers of cases. Care should be taken not to oversell the po-
tential for therapeutic outcome trials as the primary or only long-
term goal for this consortium, particularly given the logistical, fi-
nancial, and technical limitations inherent in the veterinary
neuro-oncology field. Similarly, it could be imprudent to assign
go/no-go decisions for the continuation of consortium activities
that are linked to the outcomes of experiments that have yet to
be defined. The National Academies workshop on comparative
oncology highlighted a number of critical gaps in the field,
most notably characterization of the molecular landscape of ca-
nine cancers. We agree that definition of the critical similarities
and differences that may exist in histopathological characteriza-
tion and key molecular pathways is an early and important pri-
ority. However, there are still several important facets of canine
brain cancer that make this approach a valuable complement to
traditional animal models. A significant body of published work
indicates where successes exist in the application of the compar-
ative approach to brain tumor research for the purposes of drug
development and delivery techniques.31–36 An ongoing priority
will be the advocacy and dissemination of such data to the larger
brain tumor community to maintain momentum of this
consortium.
In summary, a commitment to collaboration has been es-
tablished among veterinarians involved in canine brain tumor
patient management and physician investigators. Translational
and basic research is clearly needed for an improved under-
standing of natural disease progression and how clinical obser-
vations can be leveraged for the development of novel
treatment strategies for both dogs and humans. Further, ac-
knowledgment and appreciation of the unique strengths and
opportunities that exist between species and among veterinar-
ians and physicians are keys to establishing a consensus of
what comparative aspects are most important to the field.
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